These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 29696695)

  • 21. The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides.
    Brown CJ; Srinivasan D; Jun LH; Coomber D; Verma CS; Lane DP
    Cell Cycle; 2008 Mar; 7(5):608-10. PubMed ID: 18256546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting protein-protein interactions: lessons from p53/MDM2.
    Murray JK; Gellman SH
    Biopolymers; 2007; 88(5):657-86. PubMed ID: 17427181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
    Lu Y; Nikolovska-Coleska Z; Fang X; Gao W; Shangary S; Qiu S; Qin D; Wang S
    J Med Chem; 2006 Jun; 49(13):3759-62. PubMed ID: 16789731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53.
    Zondlo SC; Lee AE; Zondlo NJ
    Biochemistry; 2006 Oct; 45(39):11945-57. PubMed ID: 17002294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring Ligand-Induced Protein Ordering in Drug Discovery.
    Grace CR; Ban D; Min J; Mayasundari A; Min L; Finch KE; Griffiths L; Bharatham N; Bashford D; Kiplin Guy R; Dyer MA; Kriwacki RW
    J Mol Biol; 2016 Mar; 428(6):1290-1303. PubMed ID: 26812210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors.
    Kannan S; Partridge AW; Lane DP; Verma CS
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition.
    Macchiarulo A; Giacchè N; Carotti A; Baroni M; Cruciani G; Pellicciari R
    J Chem Inf Model; 2008 Oct; 48(10):1999-2009. PubMed ID: 18826207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
    Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
    J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
    Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
    J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide.
    Liu Z; Olejniczak ET; Fesik SW
    Protein Expr Purif; 2004 Oct; 37(2):493-8. PubMed ID: 15358376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations.
    Espinoza-Fonseca LM; Trujillo-Ferrara JG
    Biopolymers; 2006 Nov; 83(4):365-73. PubMed ID: 16817233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NMR structure of a complex between MDM2 and a small molecule inhibitor.
    Fry DC; Emerson SD; Palme S; Vu BT; Liu CM; Podlaski F
    J Biomol NMR; 2004 Oct; 30(2):163-73. PubMed ID: 15557803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction.
    Galatin PS; Abraham DJ
    Proteins; 2001 Nov; 45(3):169-75. PubMed ID: 11599019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-terminal region of USP7/HAUSP is critical for deubiquitination activity and contains a second mdm2/p53 binding site.
    Ma J; Martin JD; Xue Y; Lor LA; Kennedy-Wilson KM; Sinnamon RH; Ho TF; Zhang G; Schwartz B; Tummino PJ; Lai Z
    Arch Biochem Biophys; 2010 Nov; 503(2):207-12. PubMed ID: 20816748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P53 mdm2 inhibitors.
    Khoury K; Dömling A
    Curr Pharm Des; 2012; 18(30):4668-78. PubMed ID: 22650254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Helix stabilized, thermostable, and protease-resistant self-assembled peptide nanostructures as potential inhibitors of protein-protein interactions.
    Jeong WJ; Lee MS; Lim YB
    Biomacromolecules; 2013 Aug; 14(8):2684-9. PubMed ID: 23844716
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule inhibitors of the p53-MDM2.
    Hu CQ; Hu YZ
    Curr Med Chem; 2008; 15(17):1720-30. PubMed ID: 18673221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction.
    Pettersson M; Quant M; Min J; Iconaru L; Kriwacki RW; Waddell MB; Guy RK; Luthman K; Grøtli M
    PLoS One; 2015; 10(10):e0137867. PubMed ID: 26427060
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural details on mdm2-p53 interaction.
    Chi SW; Lee SH; Kim DH; Ahn MJ; Kim JS; Woo JY; Torizawa T; Kainosho M; Han KH
    J Biol Chem; 2005 Nov; 280(46):38795-802. PubMed ID: 16159876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.